Medicus reported a $15.2 million quarterly loss, but also named CD228V its main development priority under a Pfizer agreement. Nasdaq compliance returned after a share consolidation, and the SkinJect combination remains only a proposal, so the updates point in different directions.
The Pfizer agreement gives Medicus a partner for its main development program. Restored Nasdaq compliance helps its listing, though it followed a share consolidation rather than stronger business results. The SkinJect combination remains only a proposal, and the report gives no cash balance to show how long Medicus can fund its work. These updates point in different directions.
The report says Pfizer has a co-development and licensing agreement with Medicus, but gives no deal terms or expected financial effect. It does not show a clear change for Pfizer.
Follow Medicus Pharma (MDCX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MDCX